Your trusted source for investing success
Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.
Click here to get your free report!Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.
By Shelly Kumar
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that effective immediately its common shares have been approved for trading on OTCQX®, the highest tier of the OTC market, exclusively for US and international companies that undergo a rigorous financial and qualitative review. The Company’s common shares will
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it is now beginning work on a technological development research project at Ryerson University, with the goal of developing and validating technologies that are able to quantify micronutrient and heavy metal content in the cannabis plant, in
By Shelly Kumar
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) (“Beleave” or the “Company”) is pleased to be a sponsor and supporter of the Don’t Drive Hicampaign, a campaign aimed to reduce cannabis impaired driving. With legislation for legalizing marijuana progressing, the year-long Don’t Drive Hicampaign is backed by prominent sponsors including advertising agency BBDO,
By Pia Rivera
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) (“Beleave” or the “Company”) is pleased to announce that since receiving its cultivation license, the growing space at its facility near Hamilton, Ontario has been prepared, and rooted starting material has been planted.
By Shelly Kumar
Beleave Inc. (CNSX:BE)(“Beleave” or the “Company”) recently received its Health Canada license to cultivate cannabis, and is pleased to provide shareholders with a corporate update that includes an overview of the Company’s outlook for the remainder of the year.
“Our cultivation experts will remain committed to producing a high-quality product and,
By Pia Rivera
Beleave Inc. (CSE:BE)(CSE:BE.CN)(CNSX:BE) is pleased to announce that its wholly-owned subsidiary, First Access Medical Inc. (“FAM”), has been granted a licence to cultivate medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”).
Beleave Inc. (CNSX:BE) is pleased to announce that it has entered into an interim streaming agreement with PanCann Streaming Corp. (“PanCann”) to finance the purchase and construction of a proposed second production facility to be identified, in exchange for equity participation in, and a production yield allocation from the proposed
Beleave Inc. (CNSX:BE) (“Beleave” or the “Company”) is pleased to announce that it has entered into an interim streaming agreement with PanCann Streaming Corp. (“PanCann”) to finance the purchase and construction of a proposed second production facility to be identified, in exchange for equity participation in, and a production yield allocation
Beleave Inc. (“Beleave”) (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it will begin a clinical research program with Dr. Mohit Bhandari, to investigate the therapeutic use of cannabinoids for management of pain in musculoskeletal disorders. In North America, Europe, and Australia, chronic non-cancer pain is a
Toronto, ON – March 10th, 2017 – Beleave Inc. (CNSX:BE) is pleased to announce that Health Canada has scheduled a pre-license inspection of Beleave’s facility on March 15, 2017.
Toronto, ON – March 6th, 2017 – Beleave Inc. (CNSX:BE) is pleased to announce that it is now beginning work on a second drug standardization research project with Ryerson University, with the goal of developing highly purified formulations of medicinal compounds.
Beleave (CSE:BE) announced a new drug standardization research project with Ryerson University with the goal of developing highly purified formulations of medicinal compounds.
Beleave Inc. (CNSX:BE) at the request of the Investment Industry Regulatory Organization of Canada wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
Toronto, ON – February 8th, 2017 – Beleave Inc. (CNSX:BE) is pleased to announce that it will begin a collaborative research project with Dr. Lesley Campbell, associate professor in the Department of Chemistry and Biology at Ryerson University, with the goal of developing new Cannabis sativa breeding tools for Beleave,
Beleave Inc. (CNSX:BE) is pleased to announce that after receiving its affirmation letter, as announced September 26, 2016, its wholly owned subsidiary First Access Medical Inc. (“FAM”) has completed all security installations, record keeping software, and implemented required good manufacturing practices at its 14,500-square foot facility in Flamborough, ON (the
Beleave Inc. (CNSX:BE) has successfully completed a Natural Sciences and Engineering Research Council (NSERC) Engage funded research project in collaboration with lead investigator Dr. Lesley Campbell, associate professor in Ryerson University’s department of chemistry and biology. In this work, Beleave and the Campbell lab have worked on optimizing methods for
